Peptide reagent enabling a primary Epstein-Barr virus infection to be detected by testing for the corresponding antibodies, and method for using this reagent
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 8, 2002
Grant Date -
N/A
app pub date -
Aug 15, 1997
filing date -
Jan 4, 1995
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The use of a peptide reagent for detecting the presence or absence of a primary Epstein-Barr virus infection in a patient by testing for IgM antibodies, recognizing said reagent, in a biological sample from the patient according to a per se known method based on the formation of at least one antigen-antibody complex, is disclosed. The reagent contains a peptide recognized by at least one antibody to a peptide having the sequence of formula (II): Leu Glu Ile Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Cys Arg Ala Lys Phe Lys Gln. The reagent enables such a primary infection to be detected very early.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully